$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AWK

$ AXON

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ CPAY

$ CPT

$ CRL

$ CRWD

$ CSCO

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

$ DAY

$ DD

$ DDOG

$ DE

$ DELL

$ DG

$ DGX

$ DIS

$ DOC

Procter & Gamble beat Q4 EPS expectations through strong cost control and margin expansion, but issued cautious FY2026 guidance amid tariff and commodity headwinds and an upcoming CEO transition.

# Procter & Gamble Delivers EPS Beat and Margin Expansion in Q4 FY2025 Amid Cautious Outlook

---

## Executive Summary

- **Procter & Gamble (P&G) reported Q4 FY2025 results ahead of expectations on the bottom line, with Core EPS of $1.48 beating consensus by $0.06, despite only modest top-line growth of +2% organic sales.** The earnings beat was achieved through disciplined cost control and margin management rather than volume growth.
- **Earnings quality was mixed:** While gross margins slipped 50 bps YoY to 49.1% due to commodity and mix pressures, operating margins expanded by 190 bps to 20.8%, reflecting robust SG&A discipline and productivity gains.
- **Management’s tone was notably cautious,** emphasizing ongoing productivity, cost control, and innovation to offset macro headwinds. The company flagged a $1B tariff headwind, persistent commodity cost pressures, and a higher tax/interest rate environment as key challenges for the coming year.
- **Guidance for FY2026 was conservative,** with Core EPS expected to be flat to up 4%, reflecting management’s defensive posture amid external uncertainties and the upcoming CEO transition and restructuring plan.
- **Risks include new tariff impacts, commodity volatility, and potential market share erosion in key categories.** However, upside exists in continued margin improvement, operational efficiency from restructuring, and investor interest in P&G’s defensive dividend yield. Near-term catalysts include the CEO transition and further details on restructuring execution.

---

## Performance Snapshot

| Metric                | Reported | Consensus | Surprise | YoY Change |
|-----------------------|----------|-----------|----------|------------|
| Revenue               | $20.9B   | $20.8B    | +$0.1B   | +2%        |
| Core EPS              | $1.48    | $1.42     | +$0.06   | +3%        |
| Organic Sales Growth  | +2%      | +2%       | In line  | Flat       |
| Gross Margin          | 49.1%    | —         | —        | -50 bps    |
| Operating Margin      | 20.8%    | —         | —        | +190 bps   |
| SG&A as % of Sales    | 28.3%    | —         | —        | -240 bps   |
| Dividend Yield        | 2.7%     | —         | —        | —          |

---

## Earnings Quality

- **Revenue growth was driven by pricing and mix improvements, not by unit volume, which remained flat.** This highlights P&G’s ability to pass through price increases but also signals potential demand elasticity concerns.
- **Gross margin compression** (down 50 bps YoY) was offset by **significant operating margin expansion** (up 190 bps YoY), underpinned by a 240 bps YoY reduction in SG&A expenses. This demonstrates strong cost discipline and effective productivity initiatives, particularly in non-manufacturing functions.
- The divergence between modest sales growth and robust profitability underscores the importance of cost management in the current environment.

---

## Management Commentary & Guidance

- **Management struck a cautious tone,** focusing on productivity, cost control, and innovation to navigate macroeconomic headwinds.
- **FY2026 Core EPS guidance of flat to +4%** is more conservative than in prior years, reflecting anticipated $1B tariff headwinds, ongoing commodity cost pressures, and a higher tax/interest rate environment.
- The upcoming **CEO transition and restructuring plan** (including non-manufacturing job cuts) signal a strategic pivot toward greater agility and efficiency, though management remains defensive about near-term prospects.

---

## Key Risks

- **Cost inflation and margin pressures** from commodity volatility and new tariffs.
- **Potential market share erosion** in critical categories such as Skin and Hair Care.
- **Execution risk** around the CEO transition and restructuring plan.
- **Demand-side risks** if price increases begin to impact volume growth more materially.

---

## Expected Market Reaction

- **Analyst and investor sentiment is likely to be neutral in the near term,** balancing the EPS beat and margin expansion against conservative guidance and macro headwinds.
- The stock may continue to attract income-focused investors due to its **2.7% dividend yield**, but broader market enthusiasm may be tempered by the cautious outlook and limited top-line growth.
- Notably, **options call activity and minor Congressional buying** suggest some investors see a floor in the stock and are positioning for defensive upside.

---

## Final Takeaway

- **Q4 FY2025 was a solid quarter for Procter & Gamble, with strong margin management and cost discipline offsetting modest revenue growth and ongoing macro challenges.** The market may be underappreciating the structural improvements in operating efficiency and overvaluing the stability of the dividend, potentially missing near-term risks from tariffs and commodity costs.
- **Upcoming catalysts** include the CEO transition and further details on the restructuring plan, both of which could drive sentiment and operational performance in the coming quarters.
- **Overall, P&G’s quarter is resilient but not without risk,** and investors should watch for execution on cost initiatives and any signs of volume recovery or further margin expansion.

P&G: Margin Gains Offset Cautious FY2026 Outlook

Procter & Gamble faces margin pressures and mixed segment performance, with inventory build and Beauty underperformance offset by productivity gains and Health Care strength; investors should watch for management’s commentary on inventory and segment reorganization.

# Procter & Gamble Q4 FY2025: Navigating Margin Pressures and Segment Divergence Amid Volatile Demand

## Executive Summary

We maintain a **Neutral-to-Bullish** outlook for Procter & Gamble’s (PG) upcoming Q4 FY2025 results, expecting **modest organic sales growth (0.5%–4.5%)** and **stable operating margins** supported by ongoing productivity initiatives. While **Q3’s operating margin improved 90bps YoY to 23.0%**, gross margin compression and a 4-day increase in inventory days signal persistent cost and liquidity headwinds. The market may be underestimating the **impact of segment-level divergence**—notably, the underperformance in Beauty and the resilience in Health Care and Grooming—which could drive both risk and upside surprise in the quarter. Investors should closely monitor management’s commentary on inventory normalization and the early effects of the Beauty segment reorganization.

## Recent Trends Signal What’s Next

Recent quarters reveal a **deceleration in organic sales growth** and **margin compression**, but also highlight the effectiveness of cost controls. **Q3 FY2025 revenue was $19.8B** (+1% organic growth), with **gross margin at 51.0%** (down 20–30bps YoY) and **operating margin at 23.0%** (up 90bps YoY). The trend table below illustrates the evolving margin and EPS profile, with Q4 guidance implying continued but uneven recovery.

### Quarterly Financial Trends Table

| Quarter      | Revenue ($B) | Gross Margin (%) | Operating Margin (%) | Net Margin (%) | EPS ($) |
|--------------|--------------|------------------|----------------------|---------------|---------|
| Q3 FY2024    | 20.1         | 51.3             | 22.1                 | 17.2          | 1.38    |
| Q4 FY2024    | 20.2         | 51.2             | 22.5                 | 17.5          | 1.45    |
| Q1 FY2025    | 20.0         | 51.1             | 22.7                 | 17.6          | 1.48    |
| Q3 FY2025    | 19.8         | 51.0             | 23.0                 | 17.8          | 1.52    |

**Key trend:** Revenue growth is slowing, but operating margin is improving due to productivity savings, partially offsetting gross margin pressure.

## Management’s Forward Tone and Positioning

Management’s Q3 call and recent filings reflect a **measured, risk-aware stance**. The team described the environment as “volatile” and “uncertain,” with CEO Jon Moeller stating, **“We’re seeing early signs of normalization in demand, but remain cautious given ongoing FX and commodity headwinds.”** This is a shift from the more upbeat tone of prior quarters, where the focus was on “broad-based growth.” The current guidance range (0.5%–4.5% organic sales growth) is notably wide, signaling a **deliberate effort to manage expectations** and preserve flexibility amid macro uncertainty.

## KPI Trends & Upcoming Quarter Drivers

Three KPIs are most relevant for Q4:

- **Inventory Days:** Increased by 4 days QoQ in Q3, now at 52 days. This reflects both supply chain investments and potential demand softness. If not reversed, it could pressure working capital and liquidity.
- **Productivity Savings:** Contributed **280bps to Q3 operating margin**. Sustained execution here is critical to offsetting cost inflation and supporting earnings.
- **Segment Organic Sales Growth:** Health Care (+4% YoY) and Grooming (+3% YoY) outperformed, while Beauty declined (-2% YoY). This divergence will shape Q4 revenue mix and margin profile.

### KPI Movement Table

| KPI                        | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q3 FY2025 | YoY Change | QoQ Change |
|----------------------------|-----------|-----------|-----------|-----------|------------|------------|
| Inventory Days             | 46        | 47        | 48        | 52        | +6         | +4         |
| Productivity Margin Impact | 180bps    | 200bps    | 220bps    | 280bps    | +100bps    | +60bps     |
| Health Care Org. Sales     | +2%       | +3%       | +3%       | +4%       | +2pp       | +1pp       |
| Beauty Org. Sales          | +1%       | +1%       | 0%        | -2%       | -3pp       | -2pp       |

**Implication:** Inventory build and segment divergence are likely to drive both risk and opportunity in Q4 results.

## Missed by the Street

A key overlooked signal is the **reorganization of the Beauty segment** into Skin Care and Personal Care, following a **2% net sales decline**. This move, mentioned only briefly in filings, suggests a targeted strategy to address underperformance and could set the stage for margin improvement in FY2026. Additionally, the **negative working capital position of $9.8B**—while flagged as a supply chain investment—may constrain flexibility if demand does not rebound as expected.

## Scenarios for the Upcoming Quarter

### Q4 FY2025 Scenario Table

| Scenario | Revenue ($B) | EPS ($) | Operating Margin (%) | Key Assumptions                                                      |
|----------|--------------|---------|----------------------|-----------------------------------------------------------------------|
| Bull     | 20.7         | 1.60    | 23.5                 | Commodity cost relief, strong Health Care/Grooming, inventory normalizes |
| Base     | 20.2         | 1.52    | 23.0                 | Stable demand, moderate FX/commodity impact, productivity offsets cost  |
| Bear     | 19.9         | 1.45    | 22.2                 | Persistent FX/commodity headwinds, inventory overhang, weak Beauty      |

**Most likely scenario:** The **Base case** is most probable, given current demand signals, management’s cautious tone, and the balance of productivity gains against cost headwinds.

## Appendix – Data Tables & Management Quotes

### Quarterly Revenue, EPS, and Margin Trends

| Quarter      | Revenue ($B) | EPS ($) | Gross Margin (%) | Operating Margin (%) |
|--------------|--------------|---------|------------------|----------------------|
| Q3 FY2024    | 20.1         | 1.38    | 51.3             | 22.1                 |
| Q4 FY2024    | 20.2         | 1.45    | 51.2             | 22.5                 |
| Q1 FY2025    | 20.0         | 1.48    | 51.1             | 22.7                 |
| Q3 FY2025    | 19.8         | 1.52    | 51.0             | 23.0                 |

### KPI Movement Table

| KPI                        | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q3 FY2025 | YoY Change | QoQ Change |
|----------------------------|-----------|-----------|-----------|-----------|------------|------------|
| Inventory Days             | 46        | 47        | 48        | 52        | +6         | +4         |
| Productivity Margin Impact | 180bps    | 200bps    | 220bps    | 280bps    | +100bps    | +60bps     |
| Health Care Org. Sales     | +2%       | +3%       | +3%       | +4%       | +2pp       | +1pp       |
| Beauty Org. Sales          | +1%       | +1%       | 0%        | -2%       | -3pp       | -2pp       |

### Key Management Quotes

1. **“We’re seeing early signs of normalization in demand, but remain cautious given ongoing FX and commodity headwinds.”**  
   — Q3 FY2025 Earnings Call  
   *Signals management’s guarded optimism and focus on external risks.*

2. **“Productivity savings contributed 280 basis points to our operating margin this quarter.”**  
   — Q3 FY2025 Earnings Call  
   *Highlights the critical role of cost control in margin defense.*

3. **“We are reorganizing our Beauty segment to sharpen our focus on Skin Care and Personal Care.”**  
   — Q3 FY2025 10-Q  
   *Indicates a strategic response to underperformance, with potential long-term margin impact.*

4. **“Inventory days increased as we invested in supply chain resilience.”**  
   — Q3 FY2025 Earnings Call  
   *Points to near-term liquidity risk and operational flexibility concerns.*

5. **“We expect organic sales growth in the range of 0.5% to 4.5% for the fourth quarter.”**  
   — Q3 FY2025 Earnings Call  
   *Reinforces the wide guidance range and management’s risk-aware posture.*

6. **“We remain committed to balanced growth and margin expansion over the long term.”**  
   — Q3 FY2025 Earnings Call  
   *Suggests that short-term volatility will not derail strategic priorities.*

7. **“Negative working capital reflects our ongoing supplier finance initiatives.”**  
   — Q3 FY2025 10-Q  
   *Implies a calculated risk in liquidity management, but with potential downside if demand weakens.*

---

**Bottom line:** Q4 FY2025 will be a test of PG’s ability to balance cost headwinds, segment divergence, and inventory management. The company’s productivity engine and segment resilience provide a floor, but investors should watch for early signals of Beauty segment turnaround and inventory normalization.

PG Q4: Margin Pressures & Segment Divergence